This potentially will identify new applications for the drug and expedite regulatory submissions.
On the Optiscan side of things, the data should support the company’ efforts to win FDA approval for its Invue device.
The good OIL on a ‘win-win’ collab Optiscan (ASX:OIL) has entered a five-year collaboration agreement with the US based Long Grove Pharmaceuticals, which provides a contrast agent for Optiscan’s fluorescence-based endomicroscopic imaging systems.
The idea of the collab is to use Long Grove’s fluorescein drug, AK-FLUOR, with Optiscan’s imaging technology in clinical studies.
This potentially will identify new applications for the drug and expedite regulatory submissions.
On the Optiscan side of things, the data should support the company’ efforts to win FDA approval for its Invue device.
Invue enables surgeons to gain real-time pathology insights and make on-the-spot decisions.
Optiscan CEO Dr Camile Farah dubs the agreement a “clear-cut win-win for both companies’ development strategies”.
OIL Price at posting:
12.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)